DescriptionRepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.
Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.
Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.
A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.
What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.
Latest Press Releases
|Period||Period Low||Period High||Performance|
|1-Month|| 0.100 +20.00% increase |
| 0.185 -35.14% decrease |
| -0.050 (-29.41%) decrease |
|3-Month|| 0.100 +20.00% increase |
| 0.245 -51.02% decrease |
| -0.110 (-47.83%) decrease |
|52-Week|| 0.100 +20.00% increase |
| 0.390 -69.23% decrease |
| -0.150 (-55.56%) decrease |